Chronic Venous Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic venous insufficiency markets are expected to exhibit a CAGR of 4.18% during 2024-2034.
The chronic venous insufficiency market has been comprehensively analyzed in IMARC's new report titled "Chronic Venous Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic venous insufficiency (CVI) is a medical condition characterized by the inadequate flow of blood from the legs back to the heart, often due to malfunctioning valves in the veins. These valves are responsible for ensuring blood flows in one direction and prevents it from pooling in the legs. When they fail, blood accumulates, leading to numerous signs and symptoms of the disease. The indications of CVI can vary but commonly include swelling in the legs, ankles, and feet, accompanied by a feeling of heaviness or aching in the affected areas. Additionally, patients may experience skin changes, such as discoloration, thickening, and the development of varicose veins. In more severe cases, venous ulcers may form, leading to open sores that are challenging to heal. Diagnosing CVI involves a thorough physical examination and medical history review, including an assessment of the patient's symptoms and risk factors. Non-invasive tests, like doppler ultrasound, can also be utilized to assess blood flow and detect any abnormalities in the veins.
The rising cases of deep vein thrombosis, in which the blood clot damages the valve in the leg vein, leading to inefficient blood flow are primarily driving the chronic venous insufficiency market. In addition to this, the increasing incidences of various associated risk factors, such as sedentary lifestyles, obesity, aging populations, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, like venoactive drugs, compression stockings, anticoagulants, etc., to manage symptoms and prevent complications of the ailment, is further bolstering the market growth. These treatments aim to alleviate pain, reduce swelling, and promote better blood circulation, thereby enhancing the quality of life for patients. Apart from this, the rising usage of physical therapies and lifestyle changes, including regular exercise and elevation of the legs to strengthen the leg muscles, improve coordination, and enhance gross motor skills, which can ultimately boost the performance of daily activities, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive techniques, such as endovenous laser ablation and sclerotherapy, since they target and close off abnormal veins to reduce symptoms and prevent the progression of the disease is expected to drive the chronic venous insufficiency market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chronic venous insufficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic venous insufficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic venous insufficiency market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic venous insufficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic venous insufficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic venous insufficiency marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic venous insufficiency market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic venous insufficiency market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic venous insufficiency market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic venous insufficiency across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic venous insufficiency by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic venous insufficiency by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic venous insufficiency across the seven major markets?
What is the size of the chronic venous insufficiency patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic venous insufficiency?
What will be the growth rate of patients across the seven major markets?
Chronic Venous Insufficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic venous insufficiency drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic venous insufficiency market?
What are the key regulatory events related to the chronic venous insufficiency market?
What is the structure of clinical trial landscape by status related to the chronic venous insufficiency market?
What is the structure of clinical trial landscape by phase related to the chronic venous insufficiency market?
What is the structure of clinical trial landscape by route of administration related to the chronic venous insufficiency market?
The chronic venous insufficiency market has been comprehensively analyzed in IMARC's new report titled "Chronic Venous Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic venous insufficiency (CVI) is a medical condition characterized by the inadequate flow of blood from the legs back to the heart, often due to malfunctioning valves in the veins. These valves are responsible for ensuring blood flows in one direction and prevents it from pooling in the legs. When they fail, blood accumulates, leading to numerous signs and symptoms of the disease. The indications of CVI can vary but commonly include swelling in the legs, ankles, and feet, accompanied by a feeling of heaviness or aching in the affected areas. Additionally, patients may experience skin changes, such as discoloration, thickening, and the development of varicose veins. In more severe cases, venous ulcers may form, leading to open sores that are challenging to heal. Diagnosing CVI involves a thorough physical examination and medical history review, including an assessment of the patient's symptoms and risk factors. Non-invasive tests, like doppler ultrasound, can also be utilized to assess blood flow and detect any abnormalities in the veins.
The rising cases of deep vein thrombosis, in which the blood clot damages the valve in the leg vein, leading to inefficient blood flow are primarily driving the chronic venous insufficiency market. In addition to this, the increasing incidences of various associated risk factors, such as sedentary lifestyles, obesity, aging populations, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, like venoactive drugs, compression stockings, anticoagulants, etc., to manage symptoms and prevent complications of the ailment, is further bolstering the market growth. These treatments aim to alleviate pain, reduce swelling, and promote better blood circulation, thereby enhancing the quality of life for patients. Apart from this, the rising usage of physical therapies and lifestyle changes, including regular exercise and elevation of the legs to strengthen the leg muscles, improve coordination, and enhance gross motor skills, which can ultimately boost the performance of daily activities, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive techniques, such as endovenous laser ablation and sclerotherapy, since they target and close off abnormal veins to reduce symptoms and prevent the progression of the disease is expected to drive the chronic venous insufficiency market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chronic venous insufficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic venous insufficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic venous insufficiency market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic venous insufficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic venous insufficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic venous insufficiency marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic venous insufficiency market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic venous insufficiency market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic venous insufficiency market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic venous insufficiency across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic venous insufficiency by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic venous insufficiency by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic venous insufficiency across the seven major markets?
What is the size of the chronic venous insufficiency patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic venous insufficiency?
What will be the growth rate of patients across the seven major markets?
Chronic Venous Insufficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic venous insufficiency drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic venous insufficiency market?
What are the key regulatory events related to the chronic venous insufficiency market?
What is the structure of clinical trial landscape by status related to the chronic venous insufficiency market?
What is the structure of clinical trial landscape by phase related to the chronic venous insufficiency market?
What is the structure of clinical trial landscape by route of administration related to the chronic venous insufficiency market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC VENOUS INSUFFICIENCY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC VENOUS INSUFFICIENCY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC VENOUS INSUFFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC VENOUS INSUFFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC VENOUS INSUFFICIENCY - UNMET NEEDS
10 CHRONIC VENOUS INSUFFICIENCY - KEY ENDPOINTS OF TREATMENT
11 CHRONIC VENOUS INSUFFICIENCY - MARKETED PRODUCTS
11.1 List of Chronic Venous Insufficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHRONIC VENOUS INSUFFICIENCY - PIPELINE DRUGS
12.1 List of Chronic Venous Insufficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 P-TEV - Verigraft AB
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC VENOUS INSUFFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC VENOUS INSUFFICIENCY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC VENOUS INSUFFICIENCY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Venous Insufficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Venous Insufficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Venous Insufficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Venous Insufficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Venous Insufficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Venous Insufficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Venous Insufficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Venous Insufficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Venous Insufficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Venous Insufficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Venous Insufficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Venous Insufficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Venous Insufficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Venous Insufficiency - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Venous Insufficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Venous Insufficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
16 CHRONIC VENOUS INSUFFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC VENOUS INSUFFICIENCY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC VENOUS INSUFFICIENCY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC VENOUS INSUFFICIENCY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC VENOUS INSUFFICIENCY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC VENOUS INSUFFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC VENOUS INSUFFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC VENOUS INSUFFICIENCY - UNMET NEEDS
10 CHRONIC VENOUS INSUFFICIENCY - KEY ENDPOINTS OF TREATMENT
11 CHRONIC VENOUS INSUFFICIENCY - MARKETED PRODUCTS
11.1 List of Chronic Venous Insufficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHRONIC VENOUS INSUFFICIENCY - PIPELINE DRUGS
12.1 List of Chronic Venous Insufficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 P-TEV - Verigraft AB
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC VENOUS INSUFFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC VENOUS INSUFFICIENCY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC VENOUS INSUFFICIENCY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Venous Insufficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Venous Insufficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Venous Insufficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Venous Insufficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Venous Insufficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Venous Insufficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Venous Insufficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Venous Insufficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Venous Insufficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Venous Insufficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Venous Insufficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Venous Insufficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Venous Insufficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Venous Insufficiency - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Venous Insufficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Venous Insufficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Venous Insufficiency - Access and Reimbursement Overview
16 CHRONIC VENOUS INSUFFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC VENOUS INSUFFICIENCY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC VENOUS INSUFFICIENCY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
